Minsheng Life Insurance
3
185M
2
0.15
1
0.33
- Areas of investment
Summary
In 2003 was created Minsheng Life Insurance, which is appeared as Corporate Investor. The leading representative office of defined Corporate Investor is situated in the Beijing. The fund was located in Asia if to be more exact in China.
Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Zelgen. Among the most popular fund investment industries, there are Biopharma, Biotechnology. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China.
The fund is constantly included in less than 2 deals per year. The important activity for fund was in 2018. Deals in the range of 50 - 100 millions dollars are the general things for fund.
The typical case for the fund is to invest in rounds with 3 participants. Despite the Minsheng Life Insurance, startups are often financed by Yingke Capital, Shenzhen Capital Group, National SME Development Fund. The meaningful sponsors for the fund in investment in the same round are Shenzhen Capital Group, Share Capital.
Investments analytics
Analytics
- Total investments
- 3
- Lead investments
- 1
- Rounds per year
- 0.15
- Follow on index
- 0.33
- Investments by industry
- Energy (2)
- Financial Services (2)
- Renewable Energy (2)
- Solar (2)
- Biotechnology (1) Show 2 more
- Investments by region
-
- China (3)
- Peak activity year
- 2023
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 12
- Avg. valuation at time of investment
- 309M
- Group Appearance index
- 0.33
- Strategy success index
- 0.57
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Zelgen | 15 Jan 2018 | Biotechnology, Health Care, Biopharma | Early Stage Venture | 61M | China, Anhui |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.